

SYNTHESIS OF SILICA PARTICLES LOADED WITH CURCUMIN AND COATED WITH PEG₇₅₀

Cătălin Ionuț Mihăescu^{*1}, Ludmila Otilia Cintează², Cristina Lavinia Nistor¹, Cristian Petcu¹, Sabina Georgiana Burlacu¹, Bogdan Trică¹, Cristina Scamoroscenco¹, Raluca Ianchiș¹, Claudia Ninciuleanu¹, Cătălina Gîfu¹ and Elvira Alexandrescu¹

¹ The National Institute for Research & Development in Chemistry and Petrochemistry ICECHIM Bucharest, 202 Spl. Independentei, 6th district, Romania

² University of Bucharest, Bld. Regina Elisabeta 4-12, Romania

*Correspondence: mihăescu_catalin96@yahoo.com; Tel: +40 723 183 903

Introduction

Mesoporous silica nanoparticles (MSN) have been the centre of studies in different scientific areas nowadays. One of the most promising domains for the study of MSN applications is nanomedicine. They have gained significant advantages over other types of nanoparticles used as transport vectors for drugs. These advantages are primarily due to the adaptable structure depending on the synthesis conditions, high specific surface area and a large pore volume. Also, the manufacture of mesoporous silica nanoparticles is simple, scalable, cost-effective and controllable. The biocompatibility character of MSN depends on several factors, such as size, shape, whether or not the particles are functionalized¹.

One of the major problems with MSN used as drug nanocarriers is the unwanted interactions with the immune system, which cause allergic or rejection reactions. These problems can be avoided, for example, by functionalization with polyethyleneglicols (PEG)². Moreover, PEG is an effective steric stabilizer, capable of reducing the coagulation rate of nanoparticles. As a result, PEG-functionalized silica nanoparticles produced by the sol-gel method have received special attention in recent years³. In this study we obtained mesoporous silica nanoparticles functionalized with PEG via a sol-gel process as transport vectors for curcumin, which are intended to be applied in treatment of Alzheimer's disease by preventing fibrillation of β amyloid peptides.

Objectives

- Synthesis of MSN via a sol-gel process;
- Variation of silica co-precursors in order to have a fine control over particles size;
- Improvement of the obtained MSNs biocompatibility by functionalization with PEG₇₅₀;
- Addition of curcumin as an active compound into the obtained transport vectors;
- Physico-chemical characterization of the obtained PEG-silica curcumin-loaded assemblies;

Methods

- The obtained transport vectors have been characterized by TEM microscopy and DLS measurements;
- In order to remove the excess of Tween 80 and DMSO, a purification process through dialysis was performed, using a membrane with MWCO of 6-8 kDa.

Sample	Tween 80 (mL)	H ₂ O (mL)	Curcumin in DMSO (μL)	Ammonia (μL)	ODTES (μL)	OTES (μL)	Buthanol (μL)	PEG ₇₅₀ -Si (μL)	Co-precursor (μL)	
									VTES	APTES
B1	0.22	10	50	100	50	-	600	-	-	10
B3	0.22	10	50	100	50	-	600	-	50	10
B4	0.22	10	50	-	50	-	600	-	-	10
B5	0.22	10	50	-	50	-	600	-	50	10
D1	0.22	10	50	100	-	50	600	-	-	10
D3	0.22	10	50	100	-	50	600	-	50	10
D4	0.22	10	50	-	-	50	600	-	-	10
D5	0.22	10	50	-	-	50	600	-	50	10
VB1	0.22	10	50	100	50	-	600	40	-	10
VB3	0.22	10	50	100	50	-	600	40	50	10
VB4	0.22	10	50	-	50	-	600	40	-	10
VB5	0.22	10	50	-	50	-	600	40	50	10
VD1	0.22	10	50	100	-	50	600	40	-	10
VD3	0.22	10	50	100	-	50	600	40	50	10
VD4	0.22	10	50	-	-	50	600	40	-	10
VD5	0.22	10	50	-	-	50	600	40	50	10

Table 1. Compositions of B, D, VB and VD series



Fig 1. Aspect of B series samples (without PEG) 24 h after synthesis



Fig 2. Aspect of VB series samples (with PEG) 24 h after synthesis




Fig 3. TEM image of B3 sample




Fig 4. DLS results of: a) B series, b) VB series, c) D series and d) VD series

Conclusions:

- Our aim was to create PEG-silica nanoparticles loaded with curcumin, with potential applications in the treatment of Alzheimer's disease;
- Tween 80 was used as a template for the in-situ produced silica network due to its biocompatibility which makes it suitable for medical applications;
- Four different sets of samples were prepared in order to study the influence of silica co-precursor over the MSNs size;
- Size and morphology of the obtained vectors were studied by TEM and DLS techniques;
- Even though ODTES has a larger chain than OTES, B series particles are smaller in size than D series particles;
- With the addition of PEG, particles' size increases;
- Future prospects of this work regard biocompatibility and release profile studies.

Acknowledgements: „This work was supported by a grant of the Ministry of Research, Innovation and Digitization, CNCS/CCCDI – UEFISCDI, project number PN-III-P2-2.1-PED-2019-4657, within PNCDI III”.

References:

1. F. Tang, L. Li, and D. Chen, "Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery," *Adv. Mater.*, vol. 24, no. 12, pp. 1504–1534, 2012.
2. J.-C. Olivier, "Drug Transport to Brain with Targeted Nanoparticles," *NeuroRX*, vol. 2, no. 1, pp. 108–119, Jan. 2005.
3. F. Branda, B. Silvestri, G. Luciani, A. Costantini, and F. Tescione, "Synthesis structure and stability of amino functionalized PEGylated silica nanoparticles," *Colloids Surf. Physicochem. Eng. Asp.*, vol. 367, no. 1, pp. 12–16, Sep. 2010.